MENU
+Compare
CANC
ETF ticker: NASDAQ
AS OF
Feb 4, 10:30 AM (EDT)
Price
$36.38
Change
-$0.00 (-0.00%)
Net Assets
150.6M

CANC stock forecast, quote, news & analysis

The investment seeks to provide long-term growth... Show more

Category: #Health
CANC
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for CANC with price predictions
Feb 03, 2026

CANC sees MACD Histogram just turned negative

CANC saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on January 28, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 21 instances where the indicator turned negative. In of the 21 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on February 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CANC as a result. In of 39 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CANC broke above its upper Bollinger Band on January 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 27 cases where CANC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CANC advanced for three days, in of 158 cases, the price rose further within the following month. The odds of a continued upward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY).

Industry description

The investment seeks to provide long-term growth. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Oncology ETF ETF is 56.79B. The market cap for tickers in the group ranges from 3.51M to 898.12B. LLY holds the highest valuation in this group at 898.12B. The lowest valued company is NOVN at 3.51M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Oncology ETF ETF was -1%. For the same ETF, the average monthly price growth was 5%, and the average quarterly price growth was 44%. AZN experienced the highest price growth at 93%, while NRIX experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the Tema Oncology ETF ETF was -1%. For the same stocks of the ETF, the average monthly volume growth was -10% and the average quarterly volume growth was -18%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 72
Price Growth Rating: 46
SMR Rating: 78
Profit Risk Rating: 76
Seasonality Score: -26 (-100 ... +100)
View a ticker or compare two or three
CANC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
United Satets
Phone
N/A
Web
www.tema.co